Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apom...
LONDON, August 3, 2018 /PRNewswire-AsiaNet/ -- Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet Neurology[1].Treatment with APO-go®/MOVAPO® (apomorphine) subcutaneous infusion for 12 weeks gave significan...